BM hematopoietic stem cells (HSCs) are multipotent cells that divide infrequently and, during homeostasis, are predominantly quiescent or even dormant. This dormant cell cycle status is thought to protect stem cells from acquiring mutations that may lead to the exhaustion of the HSC pool and/or the generation of putative cancer stem cells ([@bib55]; [@bib16]; [@bib3]; [@bib14]). The underlying mechanism of quiescence in HSCs is likely mediated by the various BM stem cell niches comprised of multiple different cell types ([@bib15]; [@bib59]; [@bib13]; [@bib32]; [@bib43]). Several signaling molecules, including TGF-β, Thrombopoietin, Angiopoietin-1, and CXCL12 (SDF-1), have been shown to be secreted by niche cells and maintain HSC quiescence by inhibiting HSC cycling ([@bib1]; [@bib46]; [@bib58], [@bib59]; [@bib44]; [@bib61]). In addition, transcription factors, such as c-Myc, and FoxOs, as well as CDK inhibitors (p18^Ink4c^, p21^CIP1^, and p57^Kip2^) have also been suggested to regulate the balance between HSC quiescence and self-renewal ([@bib54]; [@bib62]; [@bib51]; [@bib41]; [@bib37]; [@bib49]; [@bib64]). Quiescent cells are driven into cell cycle in response to hematopoietic stress conditions. Stress-induced cytokines, including type I and II IFNs and G-CSF, all promote dormant HSCs to enter an active cell cycle mode ([@bib51]; [@bib55]; [@bib17]; [@bib4]).

*PTEN* encodes a phosphatase that negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate (PIP3) and functions as a tumor suppressor by negatively regulating the Akt/PKB signaling pathway. It dephosphorylates the phospholipid PIP3 to produce PIP2, and thus it is a direct antagonist of PI3 kinase (PI3K). Previous studies have shown that both PI3K-AKT--dependent and --independent signaling pathways are regulated by PTEN ([@bib53]; [@bib21]; [@bib27]; [@bib36]). Loss of PTEN function typically leads to an increase in PI3K signaling, causing hyperplasia and tumorigenesis such as glioblastoma, prostate cancer, or T cell leukemias ([@bib29]; [@bib45]). Previous studies have proposed that the absence of PTEN activity promotes the generation of leukemic stem cells by driving unlimited self-renewal. In contrast to the leukemic situation, it was suggested that loss of *Pten* in the hematopoietic system leads to the apparent depletion of normal HSCs from the BM ([@bib60]; [@bib63]; [@bib35]; [@bib36]). Thus, it was proposed that PTEN plays opposite roles in normal HSCs and leukemic stem cells with respect to self-renewal, although the mechanism for this phenomenon still remains enigmatic. In this study, we use two conditional *Pten* loss-of-function mouse models to show that the mobilizing cytokine G-CSF is overproduced in the absence of *Pten*, which has widespread consequences for the balance of the hematopoietic system.

RESULTS
=======

Conditional elimination of the *Pten*^flox^ allele by SCL-CreERT
----------------------------------------------------------------

Previous studies investigated the role of PTEN in HSCs using the Mx1-Cre (MxCre) model carrying the IFN-α inducible Mx1 promoter, which is activated by injecting mice with polyinosine-polycytidine (pI-pC) to induce high levels of IFN-α. However, in this model, it cannot be excluded that the type I IFN signaling cascade, activated in parallel to Cre-mediated *Pten* deletion, might cross talk or synergize with the hematopoietic effects upon *Pten* loss ([@bib17]). To circumvent this issue, we generated a new genetic mouse model where *Pten* deletion is driven by the tamoxifen (Tx)-inducible Scl-CreERT allele (Scl-Cre). In this model, the Scl-Cre allele efficiently recombines floxed alleles in hematopoietic stem/progenitors and (to a lesser degree) in endothelial cells ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib19]), thus allowing the assessment of PTEN function in HSCs independently of IFN-α.

![**Conditional elimination of the *pten*^flox^ allele in the hematopoietic system using SCL-CreER^T^ and Mx-Cre.** (A) Schematic diagram of the two conditional KO approaches and description about the tissue-specific recombination efficiency (right); +, \>90%; ○, \<50%. (B) Western blot showing the efficiency of *Pten* elimination in BM and spleen. (C) Analysis of *PTEN* expression in sections of bone and spleen using immunohistochemistry. Representative figures (bone, 1 cm = 250 µM; spleen, 1 cm = 500 µM) are shown. The data presented are representative of least three different independent experiments.](JEM_20122768R_Fig1){#fig1}

Experimental (Scl-CreER^T^;*Pten*^fl/fl^) and littermate control mice (*Pten*^fl/fl^) were fed with a Tx diet starting at 4--5 wk of age. As expected, the *Pten* gene and PTEN protein were eliminated from the BM and spleen of mice, which, after Cre induction are referred to as *Pten*^ΔScl^ ([Fig. 1 B](#fig1){ref-type="fig"} and not depicted).

We then compared our new *Pten* conditional KO model to the MxCre model in which MxCre;*Pten*^fl/fl^ and littermate control mice (*Pten*^fl/fl^) were injected with pI-pC every other day for a total of five doses. As shown in [Fig. 1 (B and C)](#fig1){ref-type="fig"}, an efficient elimination of *Pten* gene and PTEN protein was achieved in the BM and spleen of mice, which after MxCre-mediated deletion are referred to *Pten*^ΔMx^ (not depicted). Our results also indicate that the two conditional KO models delete *Pten* with a similar efficiency.

*Pten*^ΔScl^ mice develop myeloproliferative disease (MPD) and T cell acute lymphoblastic leukemia/lymphoma (T-ALL)
-------------------------------------------------------------------------------------------------------------------

In *Pten*^ΔMx^ mice, lethality occurs, on average, 7.5 wk after the first pI-pC injection. In contrast, *Pten*^ΔScl^ mice lived significantly longer with a median survival of 16.5 wk ([Fig. 2 A](#fig2){ref-type="fig"}). Similar to what has been previously reported after MxCre-mediated *Pten* deletion, *Pten*^ΔScl^ mice also displayed splenomegaly ([Fig. 2 C](#fig2){ref-type="fig"}). Pathological analysis of the morphology of hematopoietic organs revealed extramedullary hematopoiesis and MPD in the spleen, and granulocytic hyperplasia in the bones of both types of *Pten* mutant mice ([Fig. 2 D](#fig2){ref-type="fig"}). In agreement with the MPD pathology, immature myeloid CD11b^+^/Gr1^+^ cells were increased in mutant spleens ([Fig. 2, D and E](#fig2){ref-type="fig"}). Consistently, in these populations *Pten* was efficiently deleted in BM and spleen. As a consequence, increased phosphorylation of AKT (on Thr308 and Ser437) and GSK3β was detected in both models, consistent with an activated PI3K--AKT signaling pathway ([Fig. 2, F--K](#fig2){ref-type="fig"}; [@bib11]).

![**Elimination of Pten using SCL-CreER^T^ causes premature lethality.** (A) Kaplan-Meyer analysis showing lethality upon *Pten* deletion in *Pten*^ΔMx^ and *Pten*^ΔScl^ mice. P \< 0.05. *n* = 6 mice each group. (B) Hematoxylin & Eosin (H&E)--stained histological sections of bone and spleen showing MPD in the spleen and granulocytic hyperplasia in the bone. R, red pulp; W, white pulp. Bars: (spleen) 200 µm; (bone) 20 µm. (C) Splenomegaly in *Pten*^ΔMx^ and *Pten*^ΔScl^ mice 4 and 7 wk after deletion, respectively. (D) Splenic CD11b^+^Gr-1^+^ cells in control or *Pten*^ΔScl^ mice. Three independent experiments, *n* = 7 controls and *n* = 6 mutants. \*\* indicates statistically significant change, P = 0.001. (E) Splenic CD11b^+^Gr-1^+^ cells in control or *Pten*^ΔMx^ mice. Three independent experiments, *n* = 8 each group. P = 0.029. (F--H) *Pten*, pAktTh308, pAktSer473, and pGSK3βSer9 levels in BM (top) and splenic (bottom) CD11b^+^Gr-1^+^ cells of *Pten*^ΔMx^ and control counterparts pI-pC injected for 15 d. Data were obtained using a detergent-based protocol (Cytofix/Cytoperm; BD). A representative FACS plot (F) and the fold change in the expression levels (G and H) are shown. Three independent experiments, *n* = 6 controls and *n* = 4 mutants. P \< 0.05 for all stainings of BM and spleen. (I--K) *Pten*, pAktTh308, pAktSer473, and pGSK3βSer9 levels in BM (top) and splenic (bottom) CD11b^+^Gr-1^+^ cells of *Pten*^ΔScl^ and control counterparts fed with Tx diet for 28 d. Data were obtained using a detergent-based protocol (Cytofix/Cytoperm). A representative FACS plot (I) and the fold change in the expression levels (J and K) are shown. Three independent experiments, *n* = 6 each group. P \< 0.05 for all stainings of BM and spleen. Data are provided as mean ± SE. Unless otherwise indicated, \* indicates statistically significant change with P \< 0.05.](JEM_20122768_Fig2){#fig2}

Intriguingly, in contrast, to *Pten*^ΔMx^ mice, all *Pten*^ΔScl^ animals developed T-ALL as early as 12 wk after deletion ([Fig. 3, A--D](#fig3){ref-type="fig"}), similar to *VEC-Cre*--mediated *Pten* deletion in fetal liver HSCs ([@bib22]). Transplantation of BM isolated from sick *Pten*^ΔScl^ mice caused 100% of NOD/SCID recipients (5/5) to die of CD4^+^ T-ALL after 3--6 wk ([Fig. 3, B and C](#fig3){ref-type="fig"}). In contrast, only 9% of the recipient mice (1/11) transplanted with the BM of sick *Pten*^ΔMx^ mice developed T-ALL ([Fig. 3 B](#fig3){ref-type="fig"}). This indicates that *Pten*^ΔMx^ BM also contains some premalignant or even malignant T-ALL clones, albeit at lower frequencies than in *Pten*^ΔScl^ BM. The reduced T-ALL malignancy detected in *Pten*^ΔMx^ mice may be related to the liver disease of *Pten*^ΔMx^ mice early on, which likely prevents the development of a full-blown T-ALL leukemia. In summary, in addition to being an important negative regulator of myelopoiesis, PTEN is predominantly a tumor suppressor for T cell leukemia and *Pten*^ΔScl^ animals serve as a novel highly penetrant model of T-ALL to identify interacting pathways and to design and test novel therapeutic approaches.

![**Elimination of Pten using SCL-CreER^T^ induces leukemia.** (A) H&E-stained histological sections of livers from *Pten*^ΔMx^, *Pten*^ΔScl^, or control mice. (B) Frequency of tumors in NOD/SCID mice after transplantation of 10^6^ BM cells of sick *Pten*^ΔScl^ mice and *Pten*^ΔMx^, *n* = 5 and *n* = 11, respectively. Data are provided as mean ± SE. (C) FACS profile showing CD4 and CD8 expression in the BM of a control NOD/SCID mouse (left) and a *Pten*^ΔScl^ transplanted NOD/SCID mouse (right). (D) H&E-stained histological sections of bone, spleen, and liver of a typical *Pten*^ΔScl^ mouse showing T-ALL.](JEM_20122768_Fig3){#fig3}

HSC quiescence is not compromised in the BM of *Pten*^ΔScl^ and *Pten*^ΔMx^ mice
--------------------------------------------------------------------------------

We then analyzed the HSC compartment (defined here as lineage^neg^Sca1^+^cKit^+^ \[LSK\] CD34^−^CD135^−^) of both *Pten*^ΔScl^ and *Pten*^ΔMx^ mice. In agreement with previous reports ([@bib8]; [@bib60]), we observed a decrease of BM HSCs over time in both *Pten*^ΔScl^ and *Pten*^ΔMx^ animals ([Fig. 4 A](#fig4){ref-type="fig"}). However, unexpectedly, no significant differences in the frequencies of quiescent (Ki67^neg^) or cycling (BrdU^+^ and/or Ki67^+^) HSCs were detected in either model ([Fig. 4, B and E](#fig4){ref-type="fig"}). Because these analyses only measure the immediate cell cycle status and may therefore not be sensitive enough to discriminate between infrequently dividing and dormant HSCs, we analyzed the frequency of dormant label retaining cells (LRCs; [@bib55]). After an initial 10-d labeling period, BrdU was removed and *Pten*^ΔScl^ and control *Pten*^fl/fl^ mice were switched onto a Tx diet for 21 d, followed by additional 49 d of chase. Analysis of the percentage of BrdU^+^LRC cells within the HSC compartment revealed not a decrease as expected, but an increase of LRCs-HSCs in *Pten*^ΔScl^ mice ([Fig. 4 C](#fig4){ref-type="fig"}). In summary, these data suggest that *Pten* deficiency does not alter the cell cycle distribution of primitive HSCs. Accordingly, the expression profile of control and *Pten*-deficient HSCs did not reveal significant differences in genes involved in cell cycle control (unpublished data). Finally, to further examine whether functional HSCs may show a differential proliferative behavior in the absence of *Pten*, mice were treated weekly with the chemotherapeutic agent 5-FU. As shown in [Fig. 4 D](#fig4){ref-type="fig"}, similar lethality kinetics in *Pten*^ΔScl^, *Pten*^ΔMx^, and control mice was observed, suggesting a similar proliferative index of HSC/P in *Pten* mutants and WT littermates. In conclusion, using the currently available methods to analyze the cell cycle of HSCs in vivo, we could not identify any significant difference in cell cycle behavior or dormancy status between normal and *Pten*-deficient HSCs.

![**Phenotypic and functional analysis of Pten-deficient HSCs.** (A) Kinetic analysis of the relative change of LSKCD34^−^CD135^−^ cells in the BM of *Pten*^ΔMx^ and *Pten*^ΔScl^ mice compared with controls (set to 100%). The asterisk indicates statistical significant change (P \< 0.05). The cross indicates that the majority of mice do not survive beyond this time point. Each dot represents the mean value obtained from three to four mice. (B) FACS plots (top) and bar graph (bottom) showing the percentage of BrdU^+^ cells within the LSKCD135^−^ population in BM and spleen after 90 min and in BM after 18 h of BrdU labeling. P = 0.99, P = 0.19, and P = 0.75, respectively. (C) Percentage of BrdU LRCs within the LSKCD34^−^CD135^−^population. Mice were initially labeled for 10 d with BrdU, followed by simultaneous induction of SCL-CreERT with Tx and 70 d of a BrdU free chase period. P = 0.02. Each dot represents a single mouse. Horizontal bars indicate mean values. (D) Kaplan-Meyer curve showing the survival of *Pten*^ΔMx^ and *Pten*^ΔScl^ mice (15 d \[Mx\] or 21 d \[Scl\] after deletion) during weekly 5-FU administration. *n* = 7 *Pten*^ΔMx^mice, *n* = 4 *Pten*^ΔScl^ mice, *n* = 4 of each control group. (E) Analysis of intracellular Ki67 expression in LSKCD135^−^ cells from BM (top, P = 0.43) and spleen (bottom, P = 0.81) of pten^ΔMx^ mice. (F) Kinetic analysis of the relative change of LSKCD34^−^CD135^−^ cells in the spleen of *Pten*^ΔMx^ and *Pten*^ΔScl^ mice compared with controls (set to 100%). The asterisk indicates statistically significant change (P \< 0.05). The cross indicates that the majority of mice do not survive beyond this time point. Each dot represents the mean value obtained from three to four mice. (G) Bar graph showing CD45.2 donor contribution 5, 7, and 9 wk after transplantation of 0.4% of total BM and 1.6% of total splenocytes of control and *Pten*^ΔMx^ mice into CD45.1 hosts. *n* = 4 each group. (H) Limiting dilution analysis of BM cells (top) and splenocytes (bottom) of pten^ΔMx^ (KO) and control (wt) mice. Values represent reconstituted mice (chimerism \> 0.5%) versus total mice transplanted. CRUs were calculated using the method of maximum likelihood. The number of mice per group is indicated. (I) Percentage of CD45.2 donor contribution 12 wk after transplantation of 2500 LSK cells of control and *Pten*^ΔMx^ mice into CD45.1 hosts. (J and K) Multilineage reconstitution after transplantation of 2500 BM (J) or splenic (K) LSK cells from pten^ΔMx^ mice. *n* = 2 controls, *n* = 3 mutants. (L) PCR analysis of DNA from FACS-sorted donor (CD45.2) splenocytes 12 wk after transplantation showing the absence of the *Pten*^flox^ but presence of the *Pten*Δ allele. (M--O) *Pten*, pAktTh308, pAktSer473, and pGSK3βSer9 levels in BM LSKCD135^−^CD34^−^ (top) or splenic LSK cells (bottom) of *Pten*^ΔMx^ and controls (pI-pC treated). A representative FACS plot (M) and the fold change in the expression levels (N and O) are shown. Three independent experiments, *n* = 6 for each group. BM: P = 0.01 *Pten*, P \> 0.05 pAktTh308, pAktSer473, and pGSK3βSer9. Spleen: P = 0.04 *Pten*, P \> 0.05 pAktTh308, pAktSer473, and pGSK3βSer9. Unless otherwise indicated, the data presented in this figure refer to at least three independent experiments using at least three mice per group. Data are provided as mean ± SE.](JEM_20122768R_Fig4){#fig4}

*Pten*^ΔScl^ and *Pten*^ΔMx^ HSCs are functional and retain basal Akt levels, but accumulate in the spleen
----------------------------------------------------------------------------------------------------------

Our results suggest that the disappearance of *Pten*-deficient HSCs in the BM is not caused by increased HSC proliferation, followed by exhaustion. To search for an alternative explanation, we examined whether *Pten* mutant HSCs might have migrated from the BM to the spleen, which is known to massively increase in *Pten* mutant animals. Indeed, the total number of LSKCD34^−^CD135^−^ cells in the spleen dramatically increased in both models after loss of *Pten*, raising the possibility that HSCs are not physically lost but rather relocate to the spleen ([Fig. 4 F](#fig4){ref-type="fig"}). To answer this question, we first assessed whether *Pten*-deficient phenotypic HSCs are functional in both locations. Indeed, although the reconstitution activity of *Pten*-deficient splenocytes was dramatically increased compared with controls, *Pten*-deficient BM contained reduced HSC activity ([Fig. 4 G](#fig4){ref-type="fig"}). To confirm these results, we performed limiting dilution experiments by transplanting into lethally irradiated recipients a limiting amount of control and mutant BM cells (0.4% of total BM) and splenocytes (1.6% of total splenocytes). As shown in [Fig. 4 H](#fig4){ref-type="fig"}, *Pten*-deficient BM contained a lower number of competitive repopulation units (CRUs) when compared with control BM. CRU numbers were, instead, increased in Pten-deficient spleen. This analysis suggests that the spatial distribution of HSCs is altered in *Pten*-deleted mice relative to control mice, whereas the absolute numbers of HSCs appear to be the same.

Assaying reconstitution of *Pten*-deficient BM beyond 9 wk is complicated by the fact that the BM already contains precancerous clones which progress after transplantation and thus are likely responsible for the observed sudden increase in chimerism. To circumvent this complication, 2,500 FACS-sorted LSK-HSCs from *Pten*^ΔMx^ and control mice were transplanted together with rescue BM. Interestingly, *Pten*-deficient HSCs showed the same multilineage reconstitution activity (with the notable exception of B cells) after 3 mo as their normal counterparts ([Fig. 4, I--L](#fig4){ref-type="fig"}), demonstrating that *Pten*-deficient BM and splenic HSCs have myelo/lymphoid reconstitution potential. In agreement with their normal function, BM LSKCD34^−^ and splenic LSK cells of *Pten*^ΔMx^ and *Pten*^ΔScl^ mice did not show an increase in the levels of P-AKTthr308, P-AKTser473, or P-GSK3βser9, despite *Pten* being deleted ([Fig. 4, M--O](#fig4){ref-type="fig"}; and not depicted). To exclude that these results could be due to a poor sensitivity of the detergent-based assay used to detect phospho-antigens, we further evaluated AKT levels by using an alternative paraformaldehyde/acetone method ([@bib30]). However, with this method, AKT activation was also exclusively found in *Pten*-deficient myeloid cells and not in HSCs (unpublished data). Surprisingly, these data indicate that PI3K-Akt signaling is not significantly up-regulated in *Pten*-deficient HSCs. Collectively, these results suggest that *Pten*-deficient HSCs are functional and retain basal levels, but not significantly increased P-AKT levels, and are predominantly localized in the spleen rather than in the BM. To further address whether *Pten* deletion in the stromal compartment contributes to HSCs relocalization to the spleen, we performed reverse chimeras experiments. Wild-type cells were transplanted into lethally irradiated *Pten*^flox2^ or MxCre;*Pten*^flox2^ hosts, and after hematopoietic reconstitution, *Pten* deletion was induced by pI-pC ([Fig. 5 A](#fig5){ref-type="fig"}). Although *Pten* was efficiently deleted in BM stroma ([Fig. 5 B](#fig5){ref-type="fig"}), *Pten*^ΔMx^ and control recipients presented a similar number of donor-derived LSK cells in their spleens ([Fig. 5 C](#fig5){ref-type="fig"}). Moreover, no changes in the distribution of donor-derived mature splenic cells were observed in *Pten*^ΔMx^ recipients ([Fig. 5 D](#fig5){ref-type="fig"}). These data show that *Pten* loss--induced relocalization of HSCs to the spleen is due to a hematopoietic cell autonomous mechanism.

![**Pten loss mobilizes HSCs in a hematopietic cell--autonomous manner.** (A) Experimental setup used to generate reverse chimeras. (B) PTEN expression in BM stromal cells by Western blot. (C) Percentage of donor-derived wild-type LSK cells isolated from control and MxCre;pten^Δ^ hosts. black, co-host; blue, MxCre;pten^Δ^ host. P \> 0.05. *n* = 3 MxCre;pten^Δ^, *n* = 3 control mice. (D) Percentages of donor-derived wild-type mature granulocytes, B cells, and CD4 T cells in spleens isolated from control and MxCre;pten^Δ^ hosts. P \> 0.05. *n* = 3 MxCre;pten^Δ^, *n* = 3 control mice. Data are provided as mean ± SE.](JEM_20122768_Fig5){#fig5}

*Pten* deletion increases expression of mobilizing cytokines
------------------------------------------------------------

Accumulation of normal HSCs in the spleen is observed after BM injury and establishment of extramedullary hematopoiesis, or in response to high levels of mobilizing cytokines such as G-CSF. Therefore, we examined whether the level of this cytokine was increased after *Pten* deletion. As shown in [Fig. 6 (A and B)](#fig6){ref-type="fig"}, *Pten* mutant CD11b^+^Gr1^+^ BM cells produced significantly higher G-CSF levels as compared with their control counterparts ([Fig. 6, A and B](#fig6){ref-type="fig"}; and not depicted). To examine whether other cytokines were increased in *Pten*-deficient serum, a cytokine antibody array screen was used to simultaneously study the expression of 62 cytokines. This global analysis revealed that, in addition to G-CSF, levels of both CXCL12, and the mouse analogue of human IL-8, known as keratinocyte-derived chemokine (KC), were elevated ([Fig. 6 C](#fig6){ref-type="fig"}). The results obtained in this screen were then validated by flow cytometry. As shown in [Fig. 6 D](#fig6){ref-type="fig"}, MCP-5 was significantly increased in mutant splenic Gr-1^high^CD115^−^ and CD4^+^/CD8^+^ cells. In addition, a threefold up-regulation of IL-9 occurred in mutant BM myeloid cells and lymphoid cells ([Fig. 6 D](#fig6){ref-type="fig"}) and *Pten*-deficient osteoblasts and endothelial cells produced higher levels of CXCL12 ([Fig. 6 E](#fig6){ref-type="fig"}). In summary, the up-regulation of cytokine production, including G-CSF, provides a mechanistic explanation for the observed mobilization of *Pten*-deficient HSCs from the BM to the spleen.

![**Increased level of mobilizing cytokines in pten^ΔMx^ and pten^ΔScl^ mice.** (A and B) FACS plot (A) and histogram showing GCSF expression in BM CD11b^+^Gr-1^+^ cells of control and *Pten*^ΔMx^ mice. Two independent experiments were done for controls (*n* = 7) and mutants (*n* = 8; \*\*\* indicates statistically significant change, P = 0.0008). (C) Cytokine array screen showing serum levels of indicated cytokines 15 d (*Pten*^ΔMx^) or 28 d (*Pten*^ΔScl^) after deletion. This screen has been performed once with *n* = 2 per group. (D) MCP-5 and IL-9 levels in splenic Gr-1^high^/CD115^−^ and CD4^+^CD8^+^ cells or BM CD11b^+^Gr-1^+^ and CD4^+^CD8^+^ cells of *Pten*^ΔScl^ mice and control counterparts. Data are shown as fold change as compared with control levels. P = 0.01, MCP-5 in Gr-1^high^/CD115^−^ cells. P = 0.007, MCP-5 in CD4^+^CD8^+^ cells. P = 0.03, IL-9 in BM CD4^+^CD8^+^ cells. P = 0.04, IL-9 in BM CD11b^+^Gr-1^+^ cells. Three independent experiments were performed, *n* = 11 controls and *n* = 6 mutants. (E) CXCL-12 levels observed in osteoblasts (CD45^−^CD31^−^Ter119^−^CD51^+^Sca-1^−^ cells) and endothelial cells (CD45^−^Ter119^−^CD31^+^) of *Pten*^ΔMx^ mice and controls. Data are shown as fold change as compared with control levels. Two independent experiments (5 controls and 10 mutants) were performed. P \< 0.01, osteoblasts, P \< 0.05 endothelial cells. Data are provided as mean ± SE. Unless otherwise indicated, \* indicates statistically significant change with P \< 0.05.](JEM_20122768_Fig6){#fig6}

Genetic elimination of G-CSF rescues *Pten* loss--induced phenotypes
--------------------------------------------------------------------

Next, we examined whether the genetic lack of G-CSF could rescue the phenotype observed in *Pten*^ΔMx^ and *Pten*^ΔScl^ mice. *Pten^ΔMx^;G-CSF^−/−^* double-mutant mice did not develop splenomegaly ([Fig. 7, A and B](#fig7){ref-type="fig"}), nor did they massively increase the number of splenic CD11b^+^Gr-1^+^ cells ([Fig. 7, C and D](#fig7){ref-type="fig"}). Importantly, *Pten^ΔMx^;G-CSF^−/−^* mice did not accumulate LSKCD34^−^CD135^−^ cells in their spleens ([Fig. 7 E](#fig7){ref-type="fig"}). Similarly, *Pten^ΔScl^;G-CSF^−/−^* mice showed no significant increase in spleen size when compared with control animals ([Fig. 7, F and G](#fig7){ref-type="fig"}). Moreover, *Pten^ΔScl^;G-CSF^−/−^* animals did not accumulate CD11b^+^Gr-1^+^ cells in their spleen as observed in *Pten^ΔScl^;G-CSF^+/+^* mice ([Fig. 7, H and I](#fig7){ref-type="fig"}). As expected, *Pten^fl/fl^;G-CSF^−/−^* mice only demonstrated a modest nonsignificant decrease in the number of splenic immature myeloid cells ([Fig. 7, H and I](#fig7){ref-type="fig"}). Additionally, the significant accumulation of LSKCD34^−^CD135^−^ cells observed in the spleen of *Pten^ΔScl^;G-CSF^+/+^* mice did not occur in the absence of G-CSF ([Fig. 7 J](#fig7){ref-type="fig"}). Consistent with these observations, *Pten^ΔScl^;G-CSF^−/−^* mice showed a moderate increase in the numbers of BM LSKCD34^−^CD135^−^ cells when compared with *Pten^ΔScl^;G-CSF^+/+^* animals ([Fig. 7 K](#fig7){ref-type="fig"}). Importantly, *Pten^ΔScl^;G-CSF^−/−^* mice did not significantly differ in the numbers of splenic or BM HSCs compared with controls ([Fig. 7, J and K](#fig7){ref-type="fig"}).

![**In the absence of G-CSF, the Pten mutant phenotype is rescued.** (A) Spleens of *Pten*^fl/fl^, *Pten*^fl/fl^;G-CSF^−/−^, *Pten*^ΔMx^;G-CSF^−/−^, or *Pten*^ΔMx^;G-CSF^+/+^ 15 d after deletion. (B) Splenic cellularity of *Pten*^fl/fl^, *Pten*^fl/fl^;G-CSF^−/−^, *Pten*^ΔMx^;G-CSF^−/−^, or *Pten*^ΔMx^;G-CSF^+/+^ 15 d after deletion. *Pten*^fl/fl^ versus *Pten*^ΔMx^;G-CSF^+/+^, P = 0.02. *Pten*^ΔMx^;G-CSF^+/+^ versus *Pten*^ΔMx^;G-CSF^−/−^, P = 0.04. *Pten*^fl/fl^ versus *Pten*^fl/fl^ G-CSF^−/−^, P = 0.36. (B--E) Four independent experiments, *n* = 7 each group. (C and D) Percentages of CD11b^+^Gr-1^+^ cells in the spleens of *Pten*^fl/fl^, *Pten*^fl/fl^;G-CSF^−/−^, *Pten*^ΔMx^;G-CSF^−/−^, or *Pten*^ΔMx^;G-CSF^+/+^ 15 d after deletion. *Pten*^fl/fl^ versus *Pten*^ΔMx^;G-CSF^+/+^, P = 0.01. *Pten*^ΔMx^;G-CSF^+/+^ versus *Pten*^ΔMx^;G-CSF^−/−^, P = 0.01. *Pten*^fl/fl^ versus *Pten*^fl/fl^ G-CSF^−/−^, P = 0.29. (E) Relative changes in splenic LSKCD34^−^CD135^−^ levels. *Pten*^fl/fl^ versus *Pten*^ΔMx^;G-CSF^+/+^, P = 0.04. *Pten*^ΔMx^;G-CSF^+/+^ versus *Pten*^ΔMx^;G-CSF^−/−^, P = 0.04. *Pten*^fl/fl^ versus *Pten*^fl/fl^ G-CSF^−/−^, P = 0.07. (F) Spleens of *Pten*^ΔMx^;G-CSF^−/−^ or *Pten*^ΔScl^;G-CSF^+/+^ mice or their control counterpart *Pten*^fl/fl^ and or *Pten*^fl/fl^;G-CSF^−/−^ after 28 d of Tx diet. (G) Splenic cellularity of *Pten*^ΔMx^;G-CSF^−/−^ or *Pten*^ΔScl^;G-CSF^+/+^ mice or their control counterpart *Pten*^fl/fl^ and or *Pten*^fl/fl^;G-CSF^−/−^ after 28 d of Tx diet. *Pten*^fl/fl^ versus *Pten*^Δscl^;G-CSF^+/+^, P = 0.026. *Pten*^ΔScl^;G-CSF^+/+^ versus *Pten*^ΔScl^;G-CSF^−/−^, P = 0.047. Five independent experiments, *n* = 10 each group. (H and I) CD11b^+^Gr-1^+^ cells in the spleens of *Pten*^ΔScl^;G-CSF^−/−^, *Pten*^ΔScl^;G-CSF^+/+^, *Pten*^fl/fl^, or *Pten*^fl/fl^;G-CSF^−/−^ mice which were fed with Tx for 28 d. A representative FACS plot and a histogram are shown in E and G, respectively. *Pten*^fl/fl^ versus *Pten*^Δscl^;G-CSF^+/+^, P = 0.029. *Pten*^ΔScl^;G-CSF^+/+^ versus *Pten*^ΔScl^;G-CSF^−/−^, P = 0.002. Three independent experiments are shown, *n* = 7 each group (H and K). (J) Relative changes in the levels of LSKCD34^−^CD135^−^ in the BM and spleen of *Pten*^ΔScl^;G-CSF^−/−^, *Pten*^ΔScl^;G-CSF^+/+^, *Pten*^fl/fl^, or *Pten*^fl/fl^;G-CSF^−/−^ mice. *Pten*^fl/fl^ versus *Pten*^Δscl^;G-CSF^+/+^, P = 0.036. *Pten*^ΔScl^;G-CSF^+/+^ versus *Pten*^ΔScl^;G-CSF^−/−^, P = 0.042. (K) Relative changes in the levels of LSKCD34^−^CD135^−^ in the BM and spleen of *Pten*^ΔScl^;G-CSF^−/−^, *Pten*^ΔScl^;G-CSF^+/+^, *Pten*^fl/fl^, or *Pten*^fl/fl^;G-CSF^−/−^ mice. *Pten*^fl/fl^ versus *Pten*^Δscl^;G-CSF^+/+^, P = 0.037. *Pten*^ΔScl^;G-CSF^+/+^ versus *Pten*^ΔScl^;G-CSF^−/−^, P = 0.16. Data are provided as mean ± SE. Unless otherwise indicated, \* indicates statistically significant change with P \< 0.05.](JEM_20122768R_Fig7){#fig7}

In summary, our data suggest that loss of *Pten* promotes HSC mobilization to the spleen, which is caused by the production of G-CSF by mutant BM myeloid cells. Thus, HSC mobilization in mutants is not a cell-autonomous effect caused by the lack of *Pten* in HSCs but rather a consequence to the loss of *Pten* in myeloid and stromal cells. This, in turn, induces the secretion of cytokines that feeds back to HSCs in their BM niche leading to their mobilization to the spleen.

DISCUSSION
==========

In this study, we generated a new conditional SclCre-mediated *Pten* KO model, which enabled us to provide new mechanistic insights into the role of *Pten* in the hematopoietic stem and progenitor cells. Particularly, we show that *Pten* deletion induces production of G-CSF in myeloid cells, which subsequently leads to HSC mobilization to the spleen, followed by development of MPD and leukemia.

Although some of our data are consistent with previous studies showing that *Pten* deletion promotes MPD, leukemia development, and loss of HSCs in the BM, our data challenge the suggested mechanism in which *Pten* is put forward as an important regulator of HSC proliferation and self-renewal. ([@bib8]; [@bib60]; [@bib35]). Instead, our results suggest an indirect role for *Pten* in HSCs mobilization. *Pten* mutant mice in our hands have a normal number of quiescent and dormant HSCs, and a normal stress response after 5-FU induced myeloid ablation. Consistently, the expression profiles of control and *Pten*-deficient HSCs have revealed a strikingly overlapping pattern with only very few differentially expressed genes after *Pten* deletion (unpublished data). In agreement with these data, transplantation studies showed that *Pten*-deficient HSCs can generate all hematopoietic lineages (except mature B cells) and are fully functional. Strikingly, no activation of AKT signaling was observed on BM LSKCD34^−^ cells after *Pten* loss. Collectively, our ex vivo and in vivo studies revealed neither a significant role for PTEN in the control of the balance between HSC quiescence and self-renewal nor a critical role for HSC function, as was previously suggested ([@bib60]).

As an alternative mechanism for the observed loss of *Pten*-deficient BM HSCs, our data provide strong evidence that upon *Pten* deletion, functional HSCs are mobilized from the BM to the spleen. This is mediated by expression of several cytokines by mutant myeloid cells, which are known to mobilize HSCs. These include KC, the mouse homologue of the CXC chemokine IL-8, a chemoattractant and activator of neutrophils previously shown to rapidly induce mobilization of HSCs in mice and primates ([@bib34]). In addition, after *Pten* deletion, CXCL12, a well characterized chemoattractant for HSCs and a key mediator of HSC trafficking ([@bib33]; [@bib40]; [@bib50]), is up-regulated. Finally, and most importantly, mutant myeloid cells significantly up-regulate G-CSF, the most common mobilizing cytokine routinely used for harvesting human HSC from donors in clinical settings ([@bib40]). The exact molecular mechanisms that up-regulate G-CSF expression in myeloid cells after *Pten* loss remains to be explored. However, it may be mediated by the KC/IL-8 receptor Cxcr2, which has been previously implicated in G-CSF regulation ([@bib38]).

The role of G-CSF is critical, as *Pten* mutant cells lacking the G-CSF gene fail to significantly mobilize HSCs to the spleen. Nevertheless, G-CSF may have other functions that contribute to the phenotype. Moreover, the additional mobilizing cytokines increased upon PTEN deletion may also contribute to the egress of mutant HSCs. This phenomenon, moreover, is induced by mutant BM immature myeloid cells and does not appear to be a cell-intrinsic phenomenon of HSCs. Indeed, despite *Pten* being efficiently deleted in HSCs, no activation of the PI3K--AKT pathway could be detected. In contrast, mutant CD11b^+^Gr-1^+^ cells displayed activated Akt signaling in response to *Pten* loss. Thus, our results indicate that loss of *Pten* in BM myeloid cells is the driving force leading to G-CSF production and HSC mobilization to the spleen. In agreement with these data, recent studies revealed the crucial role of BM myeloid cells such as monocytes and macrophages in driving HSC egress from their niches ([@bib56]; [@bib9]). Interestingly G-CSF signaling in BM monocytes was shown to be sufficient to induce HSC mobilization ([@bib10]); however, the molecular mechanisms underlying these processes remain mostly uncertain.

Because AKT signaling is not altered in *Pten*-deficient HSCs, other phosphatases might be operative in HSCs. Another negative regulator of the PI3K pathway, SHIP, is a potential candidate, as it was shown to cooperate with *Pten* in B cell lymphoma ([@bib39]). Additionally the serine/threonine phosphatase PP2A negatively regulates P-AKT in human CD34^+^ progenitor cells, contributing to their motility ([@bib5]). Interestingly, our results demonstrate that HSCs and myeloid cells show a different degree of AKT activation in response to *Pten* deletion. Mammalian cells express three isoforms, AKT1, AKT2, and AKT3, with the first two being expressed in hematopoietic cells. Functional differences between these two isoforms have been shown, and AKT1 and AKT2 deletion in *Pten* heterozygous mice have different effects on tumorigenesis ([@bib8]; [@bib57]). Importantly, the amplitude of AKT inactivation by PHLPP phosphatases largely depends on the isoform type ([@bib7]). Thus, a differential expression and/or activity of the two AKT isoforms in myeloid and HSCs might explain why the two cell types show a different response to *Pten* deletion.

Several lines of evidence indicate that splenomegaly and MPD development are, at least partially, a secondary effect of *Pten* deficiency in BM myeloid cells. First, the production of G-CSF by mutant BM CD11b^+^Gr-1^+^ cells is crucial for the development of splenomegaly and MPD, as both phenomena were abolished in mice lacking G-CSF. Second, *Pten*-deficient myeloid cells do show overactive AKT signaling, which is crucial in driving MPD development ([@bib28]). The role of AKT in HSC self-renewal is controversial, as its constitutive activation was shown to deplete HSCs ([@bib28]), whereas fetal liver HSCs lacking AKT were unable to reconstitute long-term hematopoiesis ([@bib26]). Our data, showing that HSC self-renewal is maintained in the presence of a physiological level of active AKT, indicate that a fine-tuned modulation of AKT activation guarantees HSC maintenance, whereas too low or too high levels are detrimental for HSC function. In any case, PTEN does not seem to be a major regulator for AKT activity in HSCs in vivo.

The discrepancies observed between this and previous studies, with respect to HSC proliferation and AKT activation, might be due to the different genetic background used. Previous studies used mice on a clean C57BL/6 inbred background; in contrast, our data are obtained with mice on a mixed genetic background. These data may indicate that the observed effects on a C57BL/6 background are strain specific and our model might therefore better reflect the genetic complexity observed in clinical settings. This difference might be crucial, as several aspects of HSC function show genetically determined variation and HSC cycling activity, as well as HSC pool size being controlled at a genetic level ([@bib52]; [@bib12]). Similarly, strain-dependent variations affect responsiveness of primitive progenitor cells to cytokines such as SCF, Flt3 ligand, and TGF-β ([@bib24], [@bib25]; [@bib2]). Intriguingly, the mobilization response to G-CSF is also affected by genetic variation ([@bib23]). Moreover, tumor development in *Pten*-deficient mice has been demonstrated to be highly dependent on genetic background ([@bib18]; [@bib47]).

Interestingly, although in the absence of G-CSF *Pten* mutant mice do not develop splenomegaly or accumulate HSCs in their spleens, G-CSF absence did not rescue T-ALL development (unpublished data). Additional mechanisms, such as activation of Notch signaling, might be involved in this phenomenon. Mutations in NOTCH1 are the most recurrent genetic lesions in T-ALL, and a cross talk between PTEN and NOTCH1 signaling in regulating T-ALL development has been reported ([@bib42]). Furthermore, a recent study has suggested that PTEN down-regulation contributes to the activation of the oncogene c-Myc, providing another mechanism for the promotion of T-ALL in the absence of PTEN ([@bib6]).

Collectively, our data provide a novel and important mechanism for HSCs mobilization and MPD initiation, indicating that PTEN is dispensable for HSCs but critical for proliferation and cytokine production of myeloid progenitors. In conclusion, our data show that in response to *Pten* loss, BM Gr-1^+^CD11b^+^ cells hyper-activate AKT signaling and up-regulate G-CSF, which promotes HSC accumulation in the spleen, splenomegaly, and MPD development. The increased G-CSF levels are further supported by elevated CXCL-12 production by mutant stromal and endothelial cells to promote mobilization of HSCs from the BM to the spleen. Importantly, mobilized *Pten*-deficient splenic HSCs are functional, as they maintain their self-renewal activity and do not show increased AKT activation. Inhibition of AKT signaling by one of the various inhibitors in leukemia patients would therefore lead to the return of mobilized HSCs to the BM with little if any direct functional effects on the HSCs themselves.

MATERIALS AND METHODS
=====================

### Mice.

All mice were maintained in the ISREC and in the DKFZ animal facility under specific pathogen-free (SPF) conditions and housed in individually ventilated cages (HIVC). Animal procedures were performed according to protocols approved by the Swiss Bundesamt für Veterinärwesen no. 1728 and by the German authorities no. G-22/09. *Pten*^flox/flox^ (control) mice (The Jackson Laboratory) were purchased as in [@bib20] and crossed with the MxCre transgenic mice ([@bib31]) to obtain MxCre;*Pten*^flox/flox^ (mutant) mice on a mixed genetic background (∼50% C57BL/6, rest 129SV, FVB/N). IFN-α--induced deletion was induced by five i.p. injections of 10 mg/kg polyI-polyC (poly-IC; InvivoGen) every 2 d as previously described ([@bib54]). For the LRC assay, mice were BrdU labeled for 10 d using 0.8 mg/ml BrdU water (glucose), followed by a 70-d chase. 5-FU studies were performed using weekly i.p. injections of 150 mg/kg 5-Fluoro-uracil (Sigma-Aldrich). Unless otherwise stated, all control mice were littermates of analyzed mutant mice and were all treated with pI-pC. *Pten*^flox/flox^ (control) mice were crossed with the SCL-CreER^T^ transgenic mice ([@bib19]) to obtain SCL-CreER^T^;*Pten*^flox/flox^ (mutant) mice on a mixed genetic background (63% C57BL/6; 47% 129SVJ and CBA/J). Recombination was achieved by Tx diet (1 g/kg food; Sigma-Aldrich) for 20 d. G-CSF^−/−^ mice were provided by G.J. Lieschte (Australian Regenerative Medicine Institute, Victoria, Australia).

### Generation and analysis of chimeras.

B6.SJL-Ptprca-Pep3b-/BoyJ donor mice (CD45.1; The Jackson Laboratory) were purchased and maintained in the ISREC animal facility. To generate HSC chimeras, transplantation was performed using 2,500 FACS-sorted LSK-HSCs from each donor mouse, along with 2 × 10^6^ CD45.1 rescue BM cells, which were i.v. transferred into two CD45.1^+^ lethally irradiated (2 × 550 rad) recipient mice, which were been pretreated (48 h before) with anti-NK1.1 mAb. For limiting dilution transplants, the indicated dilutions of BM and SP CD45.2 cells from experimental mice were transferred i.v., along with 1.5 × 10^6^ Sca1-depleted CD45.1 BM into lethally irradiated CD45.1 recipients. To address the leukemic potential of Pten-deficient cells, control and mutant cells were transplanted into sublethally irradiated NOD/SCID recipients. All chimeric mice were maintained on antibiotics containing water (Bactrim; Roche) for 3 wk after irradiation, and long-term reconstitution of peripheral blood, BM, and spleen was analyzed 1--3 mo later. CRU frequencies were calculated using Poisson statistics and the method of maximum likelihood from the proportions of animals that were not reconstituted (\<0.5% chimerism; [@bib48]). To generate reverse chimeras, wild-type CD45.1 BM cells were transplanted into lethally irradiated *Pten*^flox2^ or MxCre;*Pten*^flox2^ mice (CD45.2). After 4 wk, the hematopoietic reconstitution was analyzed and *Pten* deletion was induced by polyI-C. 13 wk later, the chimerism was analyzed by flow cytometry. Western blotting: 10^6^ BM or SP cells were lysed in 100 µl Laemmli-buffer for 5 min at 95° for degradation, and an insulin syringe was used for homogenization. Ms*Pten* (Cell Signaling Technology), msGAPDH (EMD Millipore), and antibodies, followed by anti--mouse-HRP (Promega) and the ECL WB detection kit (GE Healthcare), were used for blot development.

### Isolation of BM, spleen, and stromal cells.

To collect BM cells, mouse legs were dissected and flesh removed, bones were crushed using a mortar and pestle, and cell suspensions were filtered before further use. Mouse spleens were isolated and crushed using the bottom of a syringe punch and filtered to obtain cell suspensions. Blood cells were collected from tail vein bleedings into tubes containing 10,0000 U/ml heparin (Sigma-Aldrich) and peripheral blood lymphocyte were isolated using a histopaque gradient (1,900 rpm, 8 min, no brake; Sigma-Aldrich). To isolate HSCs, lineage magnetic depletion was performed to enrich for lineage-negative cells. Therefore, BM cells were incubated with lineage antibodies (CD4, CD8, CD11b, Gr1, B220, and Ter119) and lineage-positive cells were removed using sheep anti--rat IgG-coated M450 Dynabeads (Invitrogen). Lineage-negative cells were stained for hematopoietic subsets, and LSK-HSCs were sorted using a FACSAria (BD). Stromal cells were obtained by three subsequent digestions of the leg bones. In brief, the bones were first digested with a solution containing Trypsin 0.1% Collagenase P and DNase (20 min at 37°C). Bones were then washed and crushed. The remaining bone fragments were then incubated with a second solution containing trypsin 0.1% and DNase (20 min at 37°). After being washed, bone fragments underwent a third digestion containing collagenase P, dispase, Hepes, and CaCl~2~ (1 h at 37°C). The cells present in the supernatant were isolated using a histopaque gradient.

### Flow cytometry and cell cycle analysis.

Cell cycle analysis on HSCs was performed using a cell surface staining in combination with BrdU or Ki67 antibodies. For BrdU analysis, mice were injected i.p. with 7.2 mg/kg BrdU (Sigma-Aldrich) before analysis. Mice were sacrificed and BM and SP cells were isolated. Lineage bead depletion was performed to enrich for lineage-negative cells. Lineage-negative cells were stained for hematopoietic subsets using lineage antibodies (see below) CD117, Sca1, and CD135. For BrdU staining, a commercial kit (BD) was used. The same BrdU kit was used to fix and permeabilize the cells and was followed by anti--human Ki67 (BD) antibody incubation overnight. For flow cytometric analysis, the four-color FACSCalibur (BD) equipped with a 488 and 635 nm laser, the six-color FACSCanto (BD) equipped with a 488 and a 633 nm laser, or the LSR (BD) flow cytometer equipped with a 488 nm and UV (305 nm) laser were used. Stromal cells were stained with CD45, Ter119, CD31, CD51, and Sca-1 antibodies (eBioscience). Osteoblasts were defined as CD45^−^Ter119^−^CD31^−^CD51^+^Sca-1^−^ and endothelial cells as CD45^−^Ter119^−^CD31^+^ cells. The intracellular expression of G-CSF, P-AKTser473, P-AKTth308, and pGSK3βser9 was detected by flow cytometry on BM cells, which were stained for extracellular surface markers and then fixed and permeabilized using the Cytofix/Cytoperm kit according to the manufacturer's instructions (BD). P-AKTser478 levels were additionally evaluated using an alternative methanol-based permeabilization protocol ([@bib30]). Statistical analysis for all flow cytometric studies was performed using a two-tailed Student's *t* test.

### Immunohistochemistry.

All histological samples were collected and fixed in 10% neutral buffered formalin solution (HT50 1--2; Sigma-Aldrich) for 2-4 h in a cold room on a rotor. For bones, an additional decalcification step in 0.4 M EDTA, pH 7.2, for 4--6 d at 4°C was performed on a rotor. For immunohistochemistry, slides were pretreated with peroxidase blocking buffer (120 mM Na~2~HPO~4~, 43 mM citric acid, 30 mM NaN~3~, and 0.2% H~2~O~2~, pH 5.8) prior to antigen retrieval (20 min at 70°C, 10 mM citrate buffer, pH 6.0) and then sections were incubated with a rabbit polyclonal *Pten* antibody (Neomarkers, 1:200; LAB VISION), followed by an anti--rabbit HRP (Dako). DAB (Sigma-Aldrich) was used to reveal staining, and Mayers Hematoxylin (Sigma-Aldrich) was used to counterstain the nucleus. Light microscopic analysis was performed using an Axio Scope equipped with a Progress C10^plus^ camera (Carl Zeiss).

### ELISA and cytokine array.

Cytokine levels in the serum were quantified using the RayBio Mouse Cytokine Array III kit (Hoelzel Biotech) according to the manufacturer's protocol. The cytokine levels were calculated by measuring the normalized intensity of each spot, using AIDA Image Analyzer (v.4.06) software.

### Antibodies.

Gr-1 (Ly-6G, RB6-8C5)-FITC, -biotin, and -Alexa Fluor 647; Ter 119-FITC and --biotin; B220 (RA3-6B2)-FITC and -biotin; CD11b-FITC and -biotin; CD4 (clone GK1.5)-FITC and -biotin; CD8α (53.6.7)-FITC and -biotin; TCR-β (H57)--FITC; CD161 (NK1.1, PK136)-FITC and -biotin; CD45.1 (A20.1)-FITC, -biotin, -PE, or -Alexa Fluor 647; CD45.2 (ALI-4A2)-FITC, -biotin, -PE, or -Alexa Fluor 647; and TCR-γδ (GL3)--FITC and --Alexa Fluor 647 were purified and conjugated in this laboratory according to standard protocols. CD34 (RAM34)-FITC; CD135 (A2F10)-PE; CD117 (2B8)-PE and --PE-Cy5; Sca1 (D7)-APC and -biotin; CD43 (S7)-FITC, --BP1 (FG35.4)-biotin, and --IgM (11/41)-PE were all purchased from eBioscience. CD41 (MWReg30)-FITC was purchased from BD. Primary antibody anti--G-CSF was from Santa Cruz Biotechnology, Inc., and anti-pAKTthr308, -pAKTser473, and -pGSK3βser9 were from Cell Signaling Technology. Anti-CXCL12 antibodies were purchased from R&D Systems, anti--MCP-5-PE from Bioss, and IL-9--PE from BioLegend.

### Statistical analysis.

Significance levels of data were determined by Student's *t* test for the differences in mean values.
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